Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,209 shs	237,144 shs
EGRX Eagle Pharmaceuticals	$3.55	$2.35	$1.50 ▼ $3.87	$46.10M	0.83	8,170 shs	3 shs
KDMN Kadmon	$9.50	$9.50	$3.19 ▼ $9.50	$1.70B	N/A	5.11 million shs	1,052 shs
KURA Kura Oncology	$6.28 -1.3%	$6.07	$5.41 ▼ $23.48	$543.66M	0.4	1.27 million shs	1.20 million shs
SNDX Syndax Pharmaceuticals	$9.59 -2.3%	$10.05	$8.58 ▼ $25.07	$825.22M	0.7	1.85 million shs	1.51 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	0.00%	0.00%	0.00%	-4.14%	+25.66%
EGRX Eagle Pharmaceuticals	0.00%	+18.33%	+47.92%	+184.00%	-41.03%
KDMN Kadmon	0.00%	0.00%	0.00%	0.00%	0.00%
KURA Kura Oncology	0.00%	+6.26%	-2.48%	+7.35%	-71.95%
SNDX Syndax Pharmaceuticals	0.00%	+3.39%	-6.44%	-14.68%	-59.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	0.2207 of 5 stars	0.0	0.0	0.0	4.2	0.0	0.8	0.0
EGRX Eagle Pharmaceuticals	2.4687 of 5 stars	0.0	3.0	0.0	3.9	0.6	3.3	0.0
KDMN Kadmon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	4.5231 of 5 stars	4.4	2.0	0.0	4.7	2.9	0.8	0.6
SNDX Syndax Pharmaceuticals	3.1418 of 5 stars	3.5	0.0	0.0	4.4	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
KDMN Kadmon	0.00	N/A	N/A	N/A
KURA Kura Oncology	2.86	Moderate Buy	$24.50	290.13% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.30	257.66% Upside

Current Analyst Ratings Breakdown

Latest SNDX, KURA, CARA, EGRX, and KDMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
EGRX Eagle Pharmaceuticals	$257.55M	0.18	$8.88 per share	0.40	N/A	∞
KDMN Kadmon	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	$53.88M	10.09	N/A	N/A	$5.32 per share	1.18
SNDX Syndax Pharmaceuticals	$23.68M	34.85	N/A	N/A	$3.38 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KDMN Kadmon	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest SNDX, KURA, CARA, EGRX, and KDMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KDMN Kadmon	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.77	4.71
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
KDMN Kadmon	N/A	N/A	N/A
KURA Kura Oncology	0.02	8.07	8.07
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%
EGRX Eagle Pharmaceuticals	85.36%
KDMN Kadmon	N/A
KURA Kura Oncology	N/A
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	3.10%
EGRX Eagle Pharmaceuticals	28.90%
KDMN Kadmon	N/A
KURA Kura Oncology	6.40%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
KDMN Kadmon	N/A	178.52 million	N/A	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

SNDX, KURA, CARA, EGRX, and KDMN Headlines

Recent News About These Companies

Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs Group

July 13 at 2:27 AM | americanbankingnews.com

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

July 12 at 8:51 PM | msn.com

The Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)

July 10, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?

July 9, 2025 | marketbeat.com

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

July 9, 2025 | msn.com $https://www.msn.com/en-us/money/general/syndax-s-revuforj-granted-fda-priority-review-for-relapsed-refractory-mutant-npm1-aml/ar-AA1IeAsC$

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

July 8, 2025 | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26, 2025 | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25, 2025 | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 24, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/24/3104643/0/en/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

Syndax reports publication of revumenib data from BEAT AML trial

June 13, 2025 | msn.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12, 2025 | thepharmaletter.comT

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12, 2025 | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/12/3098182/0/en/syndax-presents-new-revuforj-revumenib-data-in-relapsed-refractory-mnpm1-and-nup98r-acute-leukemia-from-augment-101-trial-at-eha-2025.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX, KURA, CARA, EGRX, and KDMN Company Descriptions

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.55 0.00 (0.00%)

As of 07/11/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Kadmon NYSE:KDMN

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Kura Oncology NASDAQ:KURA

$6.28 -0.08 (-1.26%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$6.28 +0.00 (+0.08%)

As of 07/11/2025 06:24 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.59 -0.23 (-2.34%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.62 +0.03 (+0.35%)

As of 04:05 AM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time